ESC 365 - Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with mild thrombocytopenia undergoing PCI

ESC Premium Access

Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with mild thrombocytopenia undergoing PCI

Session: The guardians of clotting: exploring antiplatelet strategies

Topic: Percutaneous Coronary Intervention (PCI)

Speaker: Professor K. Chen (Tianjin, CN)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Professor Kang-Yin Chen

2nd Hospital of Tianjin Medical University, Tianjin (China)

0 follower

5 more presentations in this session

Reduction of thrombus burden by cangrelor in ticagrelor-loaded st-elevation myocardial infarction patients with high residual platelet reactivity: the imaging sub-study of the ERMIT randomized trial

Speaker: Professor F. Beygui (Caen, FR)

Disparities in the proportion of ticagrelor and prasugrel-eligible patients with NSTE-ACS in a real-world registry

The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention

Speaker: Doctor W. Dai (Tianjin, CN)

Respective impact of bleeding and ischemic complications of mortality after percutaneous coronary interventions: substudy from the FRANCE-PCI registry

Speaker: Doctor P. Guedeney (Paris, FR)

Complex versus non-complex, should we adjust the antiplatelet strategy to the type of percutaneous coronary intervention? Results from a real world PCI population

Speaker: Ms E. Woelders (Nijmegen, NL)

Access the full session

The guardians of clotting: exploring antiplatelet strategies

Speakers: Professor K. Chen, Professor F. Beygui, Doctor W. Dai, Doctor P. Guedeney, Ms E. Woelders

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources